Clinical Trial Update: Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) [Phase 1, Phase 2]

View source ↗

Summary

An open-label Phase 1/2 study (FORWARD-53) of WVE-N531 in Duchenne Muscular Dystrophy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• WVE-N531

Snippet

Sponsor: Wave Life Sciences Ltd. | Conditions: Duchenne Muscular Dystrophy | Phase 1, Phase 2 | Status: RECRUITING